Anti-Infective Product Development Is Focus Of Latest FDA Drug Review Reorg
Executive Summary
The latest reorganization within FDA’s Office of New Drugs is aimed at strengthening the agency’s focus on emerging issues in anti-infective product development.
You may also be interested in...
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves
Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves
Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.
Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews
FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.